(3R,4R,5S)-5-[(1R)-2-[(2R,3R,4R,5S)-5-[(1R)-1,2-Dihydroxyethyl]-4-[(2S,3R,4R,5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyoxolan-2-yl]oxy-3-hydroxyoxolan-2-yl]oxy-1-hydroxyethyl]oxolane-2,3,4-triol

Term ID

CHEBI:155782

Synonyms

beta-D-galacto-hexofuranosyl-(1->3)-beta-D-galacto-hexofuranosyl-(1->6)-D-galacto-hexofuranose
Galf(b1-3)Galf(b1-6)Galf

Definition

References

glygen:G99807HK
glytoucan:G99807HK

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (3R,4R,5S)-5-[(1R)-2-[(2R,3R,4R,5S)-5-[(1R)-1,2-Dihydroxyethyl]-4-[(2S,3R,4R,5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyoxolan-2-yl]oxy-3-hydroxyoxolan-2-yl]oxy-1-hydroxyethyl]oxolane-2,3,4-triol

Phenotype where environments contain (3R,4R,5S)-5-[(1R)-2-[(2R,3R,4R,5S)-5-[(1R)-1,2-Dihydroxyethyl]-4-[(2S,3R,4R,5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyoxolan-2-yl]oxy-3-hydroxyoxolan-2-yl]oxy-1-hydroxyethyl]oxolane-2,3,4-triol

Phenotype modified by environments containing (3R,4R,5S)-5-[(1R)-2-[(2R,3R,4R,5S)-5-[(1R)-1,2-Dihydroxyethyl]-4-[(2S,3R,4R,5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyoxolan-2-yl]oxy-3-hydroxyoxolan-2-yl]oxy-1-hydroxyethyl]oxolane-2,3,4-triol

Phenotype affecting (3R,4R,5S)-5-[(1R)-2-[(2R,3R,4R,5S)-5-[(1R)-1,2-Dihydroxyethyl]-4-[(2S,3R,4R,5S)-5-[(1R)-1,2-dihydroxyethyl]-3,4-dihydroxyoxolan-2-yl]oxy-3-hydroxyoxolan-2-yl]oxy-1-hydroxyethyl]oxolane-2,3,4-triol

Human Disease Model